Volume-corrected mitotic index and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors

Analytical and Quantitative Cytology and Histology

Volumn 21, Issue 5, 1999, Pages 425-429

  Miliaras, Dimosthenis ^a,b  

^a General Clinic   (Greece)

^b NONE   (Greece)

Author keywords

Mitosis; Ovarian neoplasms; P53 protein; Volume corrected mitotic index

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIATION; EPITHELIUM TUMOR; FEMALE; HUMAN; IMMUNOREACTIVITY; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INDEX; OVARY TUMOR; PRIORITY JOURNAL;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL SIZE; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MITOTIC INDEX; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

FALLOPIA;

EID: 0032747069     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Aaltomaa S, Liponen P, Eskelinen M, Cosma VM, Marin S, Alhava E, Syrjanen K: Comparison of classic and quantitative prognostic factors in hormone receptor-positive and hormone-negative female breast cancer. Am J Surg 1993; 165:307-311
2. Baak JPA, Blanco AA, Kurver PHJ, Langley FA, Boon ME, Overdiep SH, Nieuwlaat A, Brekelmans E: Quantitation of borderline and malignant mucinous ovarian tumors. Histopathology 1981;5:353-360
3. Baak JPA, Fox H, Langley FA, Buckely CH: The prognostic value of morphometry in ovarian epithelial tumors of borderline malignancy. Int J Gynecol Pathol 1985;4:186-191
4. Baak JPA, van Dop H, Kurver HJ, Hermans J: The prognostic value of morphometry to classic prognostication in breast cancer. Cancer 1985;56:374-382
5. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC: Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-236
6. Darai E, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, Scoazec JY: Expression of p53 protein in borderline epithelial ovarian tumors: A clinicopathologic study of 39 cases. Eur J Gynecol Oncol 1998;19:144-149
7. de Nictolis M, Montironi R, Tomassoni S, Valli M, Pisani E, Fabris G, Prat J: Benign, borderline, and well differentiated malignant intestinal mucinous tumors of the ovary: A clinicopathologic, histochemical, immunohistochemical, and nuclear quantitative study of 57 cases. Int J Gynecol Pathol 1994;13:10-21
8. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR: p53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol 1997;65:218-224
9. Eskelinen M, Lipponen P, Aitto-Oja L, Hall O, Syrjanen K: The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma. Int J Cancer 1993;55: 547-554
10. Fisher ER, Krieger JS, Skirpan PJ: Ovarian cystoma: Clinico-pathologic observations. Cancer 1955;8:437-445
11. Haapasalo H, Collan Y, Atkin NB, Pesonen E, Seppa A: Prognosis of ovarian carcinomas: Prediction by histoquantitative methods. Histopathology 1989;15:167-178
12. Haapasalo H, Pesonen E, Collan Y: Volume corrected mitotic index (M/V-index): The standard of mitotic activity in neoplasms. Pathol Res Pract 1989;185:551-554
13. Hart WR: Pathology of borderline and malignant tumors of the ovary. In Gynecologic Oncology. Edited by M Coppleson. Edinburgh, Churchill Livingstone, 1981, pp 633-654
14. Hart WR, Norris HJ: Borderline and malignant mucinous tumors of the ovary. Cancer 1973;31:1031-1045
15. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K: p53 Expression in epithelial ovarian neoplasms: Relation to clinical and pathologic parameters, Ki-67 expression and flow-cytometry. Gynecol Oncol 1994;53:301-306
16. Katzenstein A-LA, Mazur MT, Morgan TE, Kao MS: Proliferative serous tumors of the ovary: Histological features and prognosis. Am J Surg Pathol 1978;2:339-355
17. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S: High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992;83:978-984
18. Klemi PJ, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M: Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994;13:228-233
19. Kupryjanczyk J, Bell DA, Yendell DW, Scully RE, Thor AN: p53 expression in ovarian borderline tumors and stage I carcinoma. Gynecol Oncol 1994;52:232-236
20. Lipponen PK, Kosma VM, Collan Y, Kulju T, Kosunen O, Eskelinen M: Potential of nuclear morphometry and volume-corrected mitotic index in grading transitional cell carcinoma of the urinary bladder. Eur Urol 1990;17:333-337
21. Marcelli AR, Demopoulos RI, Goswami S, Mittal KR: Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors. Int J Gynecol Pathol 1996;15:39-44
22. Russell P: The pathological assessment of ovarian neoplasms: III. The proliferating "epithelial" tumors. Pathology 1979;11:251-282
23. Taylor HB, Norris HJ: Mesenchymal tumors of the uterus: IV. Diagnosis and prognosis of leiomyosarcomas. Arch Pathol 1966;82:40-44
24. Tomasino RM, Daniele E, Bazan V, Morello V, Tralongo V, Nuara C, Salvato M, Ingria F, Restivo S: Prognostic significance of cell kinetics in laryngeal squamous cell carcinoma: clinicopathological associations. Cancer Res 1995;55: 6103-6108
25. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC: p53 Gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994;86:1549-1551
26. Young RH, Clement PB, Scully RE: The ovary. In Diagnostic Surgical Pathology. Edited by SS Sterneberg. New York, Raven Press, 1989, pp 1655-1734